Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

被引：159

作者：

Reck, Martin ^{[1
]}

Schenker, Michael ^{[2
]}

Lee, Ki Hyeong ^{[3
]}

Provencio, Mariano ^{[4
]}

Nishio, Makoto ^{[5
]}

Lesniewski-Kmak, Krzysztof ^{[6
]}

Sangha, Randeep ^{[7
]}

Ahmed, Samreen ^{[8
]}

Raimbourg, Judith ^{[9
]}

Feeney, Kynan ^{[10
,11
]}

Corre, Romain ^{[12
]}

Franke, Fabio Andre ^{[13
]}

Richardet, Eduardo ^{[14
]}

Penrod, John R. ^{[15
]}

Yuan, Yong ^{[15
]}

Nathan, Faith E. ^{[15
]}

Bhagavatheeswaran, Prabhu ^{[15
]}

DeRosa, Michael ^{[16
]}

Taylor, Fiona ^{[16
]}

Lawrance, Rachael ^{[17
]}

Brahmer, Julie ^{[18
]}

机构：

[1] German Ctr Lung Res DZL, ARCN, LungenClin Grosshansdorf, Wohrendamm 80, D-22927 Grosshansdorf, Germany

[2] Cent Oncol Sf Nectarie, 23A Caracal St, Craiova 200347, Romania

[3] Chungbuk Natl Univ Hosp, 776,1 Sunhwan Ro, Cheongju 28644, Chungcheonbuk D, South Korea

[4] Univ Autonoma Madrid, Inst Invest Puerta Hierro, Hosp Puerta Hierro de Majadahonda, C Manuel de Falla 1, Madrid 28222, Majadahonda, Spain

[5] Japanese Fdn Canc Res, Canc Inst Hosp, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan

[6] Gdansk Med Univ, Oddzial Onkol Radioterapii Szpital, UI Powstania Styczniowego 1, PL-81519 Gdynia, Poland

[7] Cross Canc Inst, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada

[8] Univ Hosp Leicester NHS Trust, Dept Infect, Leicester LE1 5WW, Leics, England

[9] Inst Cancerol Ouest, Ctr Rene Gauducheau, Blvd Jacques Monad, F-44805 Nantes, France

[10] Notre Dame Univ, 100 Murdoch Dr, Perth, WA 6150, Australia

[11] Edith Cowan Univ, 100 Murdoch Dr, Perth, WA 6150, Australia

[12] CHU Rennes, 2 Rue Henri le Guilloux, F-35033 Rennes, France

[13] Hosp Caridade Ijui, CACON, Av David Jose Martins, BR-98700000 Ijui, RS, Brazil

[14] IONC Univ Catolica Cordoba, Parana 560 2 Piso, RA-5000 Cordoba, Argentina

[15] Bristol Myers Squibb Co, 3401 Princeton Pike, Lawrenceville, NJ 08648 USA

[16] Adelphi Values, 290 Congress St 7th Floor, Boston, MA 02210 USA

[17] Adelphi Values, Grimshaw Ln, Bollington SK10 5JB, Cheshire, England

[18] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB1-G94, Baltimore, MD 21287 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2019年 / 116卷

关键词：

Antineoplastic agents; Carcinoma; Ipilimumab; Lung neoplasms; Nivolumab; Non-small-cell lung cancer; Platinum-doublet chemotherapy; Quality of life; Surveys and questionnaires; QUALITY-OF-LIFE; DOCETAXEL; SYMPTOMS; MULTICENTER;

D O I：

10.1016/j.ejca.2019.05.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In the phase I I I CheckMate 227 study, first-line nivolumab + ipilimumab significantly prolonged progression-free survival (co-primary end-point) versus chemotherapy in patients with advanced nonesmall-cell lung cancer (NSCLC) and high tumour mutational burden (TMB; >= 10 mutations/megabase). Aim: To evaluate patient-reported outcomes (PROs) in this population. Methods: Disease-related symptoms and general health status were assessed using the validated PRO questionnaires Lung Cancer Symptom Scale (LCSS) and EQ-5D, respectively. LCSS average symptom burden index (ASBI) and three-item global index (3-IGI) and EQ-5D visual analogue scale (VAS) and utility index (UI) scores and changes from baseline were analysed descriptively. Longitudinal changes were assessed by mixed-effect model repeated measures (MMRMs) and time to first deterioration/improvement analyses. Results: In the high TMB population, PRO questionnaire completion rates were similar to 90% at baseline and >80% for most on-treatment assessments. During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) or improved following induction (EQ-5D VAS). MMRM-assessed changes in symptom burden were improved with nivolumab + ipilimumab versus chemotherapy. Symptom deterioration by week 12 was lower with nivolumab + ipilimumab versus chemotherapy (22.3% versus 35.0%; absolute risk reduction: 12.7% [95% confidence interval 2.4-22.5]), irrespective of discontinuation. Time to first deterioration was delayed with nivolumab + ipilimumab versus chemotherapy across LCSS and EQ-5D summary measures. Conclusion: First-line nivolumab + ipilimumab demonstrated early, sustained improvements in PROs versus chemotherapy in patients with advanced NSCLC and high TMB. (C) 2019 The Authors. Published by Elsevier Ltd.

引用

页码：137 / 147

页数：11

共 50 条

[41] First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
Reck, M.
Ciuleanu, T. -E.
Cobo, M.
Schenker, M.
Zurawski, B.
Menezes, J.
Richardet, E.
Bennouna, J.
Felip, E.
Juan-Vidal, O.
Alexandru, A.
Sakai, H.
Lingua, A.
Reyes, F.
Souquet, P. -J.
De Marchiy, P.
Martin, C.
Perol, M.
Scherpereel, A.
Lu, S.
Paz-Ares, L.
Carbone, D. P.
Memaj, A.
Marimuthu, S.
Zhang, X.
Tran, P.
John, T.
ESMO OPEN, 2021, 6 (05)
[42] Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Horn, Leora
Spigel, David R.
Vokes, Everett E.
Holgado, Esther
Ready, Neal
Steins, Martin
Poddubskaya, Elena
Borghaei, Hossein
Felip, Enriqueta
Paz-Ares, Luis
Pluzanski, Adam
Reckamp, Karen L.
Burgio, Marco A.
Kohlhaeeufl, Martin
Waterhouse, David
Barlesi, Fabrice
Antonia, Scott
Arrieta, Oscar
Fayette, Jerome
Crino, Lucio
Rizvi, Naiyer
Reck, Martin
Hellmann, Matthew D.
Geese, William J.
Li, Ang
Blackwood-Chirchir, Anne
Healey, Diane
Brahmer, Julie
Eberhardt, Wilfried E. E.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (35) : 3924 - +
[43] Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Wu, Yi-Long
Zhou, Caicun
Hu, Cheng-Ping
Feng, Jifeng
Lu, Shun
Huang, Yunchao
Li, Wei
Hou, Mei
Shi, Jian Hua
Lee, Kye Young
Xu, Chong-Rui
Massey, Dan
Kim, Miyoung
Shi, Yang
Geater, Sarayut L.
LANCET ONCOLOGY, 2014, 15 (02): : 213 - 222
[44] CheckMate-227 shows superior progression-free Survival for Nivolumab in Combination with Ipilimumab versus Chemotherapy in the First-line Treatment of Patients with non-small cell Lung Cancer during high Tumor Mutation Burden
不详
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (03) : 152 - 152
[45] Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3
Makharadze, Tamta
Quek, Ruben G. W.
Melkadze, Tamar
Gogishvili, Miranda
Ivanescu, Cristina
Giorgadze, Davit
Dvorkin, Mikhail
Penkov, Konstantin
Laktionov, Konstantin
Nemsadze, Gia
Nechaeva, Marina
Rozhkova, Irina
Kalinka, Ewa
Gessner, Christian
Moreno-Jaime, Brizio
Passalacqua, Rodolfo
Konidaris, Gerasimos
Rietschel, Petra
Gullo, Giuseppe
CANCER, 2023, 129 (14) : 2256 - 2265
[46] Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
Makoto Nishio
Yuichiro Ohe
Satoshi Ikeda
Toshihide Yokoyama
Hidetoshi Hayashi
Tatsuro Fukuhara
Yuki Sato
Hiroshi Tanaka
Katsuyuki Hotta
Shunichi Sugawara
Haruko Daga
Isamu Okamoto
Kazuo Kasahara
Tateaki Naito
Li Li
Ravi G. Gupta
Judith Bushong
Hideaki Mizutani
International Journal of Clinical Oncology, 2023, 28 (10) : 1369 - 1370
[47] Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
Jaenne, Pasi A.
Ou, Sai-Hong I.
Kim, Dong-Wan
Oxnard, Geoffrey R.
Martins, Renato
Kris, Mark G.
Dunphy, Frank
Nishio, Makoto
O'Connell, Joseph
Paweletz, Cloud
Taylor, Ian
Zhang, Hui
Goldberg, Zelanna
Mok, Tony
LANCET ONCOLOGY, 2014, 15 (13): : 1433 - 1441
[48] Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer
Reck, Martin
De, Tuli
Paz-Ares, Luis
Edmondson-Jones, Mark
Yuan, Yong
Yates, Georgia
Zoffoli, Roberto
Chaudhary, Mohammad Ashraf
Lee, Adam
Varol, Nebibe
Penrod, John R.
CLINICAL LUNG CANCER, 2024, 25 (07) : e362 - e368
[49] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227
O'Byrne, K. J.
Lee, K. H.
Kim, S-W.
Park, K.
Nishio, M.
Sakai, H.
Ohe, Y.
Fukuhara, T.
Kang, J-H.
Daga, H.
Yu, C-J.
Hotta, K.
Tanaka, H.
Takeda, M.
Yokoyama, T.
Nathan, F. E.
Lee, J-S.
ANNALS OF ONCOLOGY, 2020, 31 : S824 - S824
[50] CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).
Horn, Leora
Reck, Martin
Gettinger, Scott N.
Spigel, David R.
Antonia, Scott Joseph
Rupnow, Brent A.
Pieters, Anne
Selvaggi, Giovanni
Fairchild, Justin P.
Peters, Solange
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →